Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of AVITA Medical Inc (NASDAQ: RCEL) was $3.99 for the day, down -25.84% from the previous closing price of $5.38. In other words, the price has decreased by -$25.84 from its previous closing price. On the day, 1.61 million shares were traded. RCEL stock price reached its highest trading level at $4.55 during the session, while it also had its lowest trading level at $3.84.
Ratios:
Our analysis of RCEL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.46 and its Current Ratio is at 0.58.
On December 24, 2024, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 28 ’25 when McNamara Robert bought 10,000 shares for $4.50 per share. The transaction valued at 45,000 led to the insider holds 86,771 shares of the business.
O’Toole David D bought 2,000 shares of RCEL for $9,040 on Aug 26 ’25. The CFO now owns 31,657 shares after completing the transaction at $4.52 per share. On Aug 19 ’25, another insider, McNamara Robert, who serves as the Director of the company, bought 10,000 shares for $5.00 each. As a result, the insider paid 50,000 and bolstered with 76,771 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCEL now has a Market Capitalization of 107805544 and an Enterprise Value of 135107552. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.32. Its current Enterprise Value per Revenue stands at 1.804 whereas that against EBITDA is -3.006.
Stock Price History:
The Beta on a monthly basis for RCEL is 1.58, which has changed by -0.6207224 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, RCEL has reached a high of $14.16, while it has fallen to a 52-week low of $3.60. The 50-Day Moving Average of the stock is -21.37%, while the 200-Day Moving Average is calculated to be -44.08%.
Shares Statistics:
RCEL traded an average of 628.87K shares per day over the past three months and 290330 shares per day over the past ten days. A total of 26.61M shares are outstanding, with a floating share count of 24.52M. Insiders hold about 1.31% of the company’s shares, while institutions hold 31.14% stake in the company. Shares short for RCEL as of 1759190400 were 3310626 with a Short Ratio of 5.26, compared to 1756425600 on 4596834. Therefore, it implies a Short% of Shares Outstanding of 3310626 and a Short% of Float of 12.34.
Earnings Estimates
The dynamic stock of AVITA Medical Inc (RCEL) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.2 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$0.86 and -$2.73 for the fiscal current year, implying an average EPS of -$2.0. EPS for the following year is -$0.85, with 7.0 analysts recommending between $0.82 and -$2.12.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 6 analysts. It ranges from a high estimate of $32.36M to a low estimate of $26.16M. As of. The current estimate, AVITA Medical Inc’s year-ago sales were $29.31MFor the next quarter, 6 analysts are estimating revenue of $30.15M. There is a high estimate of $35.2M for the next quarter, whereas the lowest estimate is $26.16M.
A total of 10 analysts have provided revenue estimates for RCEL’s current fiscal year. The highest revenue estimate was $120.23M, while the lowest revenue estimate was $109.24M, resulting in an average revenue estimate of $114.31M. In the same quarter a year ago, actual revenue was $101.97MBased on 10 analysts’ estimates, the company’s revenue will be $153.69M in the next fiscal year. The high estimate is $182.25M and the low estimate is $125.4M.
